Want to see IRD full AI Analyst Report?
IRD Stock Chart & Stats
$3.08
$0.16(5.48%)
At close: 4:00 PM EDT
$3.08
$0.16(5.48%)
Day’s Range― - ―
52-Week Range$1.04 - $5.81
Previous CloseN/A
Volume1.09M
Average Volume (3M)1.08M
Market Cap
$306.32M
Enterprise Value$361.33
Total Cash (Recent Filing)$59.96M
Total Debt (Recent Filing)$25.93M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 07, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding82,565,834
10 Day Avg. Volume943,049
30 Day Avg. Volume1,081,647
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.23Price Target Upside264.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$15.91M
Bulls Say, Bears Say
Bulls Say
Advancing Gene Therapy PipelineOpus has a diversified IRD pipeline with multiple candidates moving toward clinic (RDH12, MERTK, RHO, plus advancing LCA5/BEST1). A portfolio approach creates multiple milestone catalysts and reduces single-program binary risk, supporting sustained value creation over the next 2–3 years if trials progress.
Secured Medium-term Financing RunwayAccess to a secured senior note facility with an initial tranche funded materially extends near-term runway and reduces immediate refinancing pressure. This funding supports multiple clinical starts and data readouts through 2027–2029, lowering the probability of disruptive emergency financing in the medium term.
Minimal Leverage / No Recent DebtHaving little to no legacy bank debt preserves financial flexibility for a development-stage biotech. Low fixed interest obligations allow management to prioritize R&D investments and structure future financings (equity or program partnerships) without being constrained by heavy debt service during lengthy clinical development.
Bears Say
Negative Stockholders' EquityNegative equity indicates accumulated losses have eroded the capital base, weakening balance-sheet resilience. This structural shortfall heightens financing risk, can limit strategic optionality, and increases the likelihood of dilutive capital raises or onerous financing terms over the coming months if clinical progress misses expectations.
Sustained Cash BurnMeaningfully negative operating and free cash flow show the company is not self-sustaining and relies on external funding. Persistent cash burn forces management to seek funding before key milestones, creating dilution or covenant risks and constraining long-term R&D planning if capital markets or partners tighten.
Declining Revenue And Unstable EarningsA sharp TTM revenue decline and a swing from prior profitability to sizable losses signal inconsistent commercial or operational performance. Reduced revenue weakens margin leverage, makes sustaining fixed R&D costs harder, and lengthens the path to sustainable profitability absent successful clinical-to-commercial transitions.
Opus Genetics News
IRD FAQ
What was Opus Genetics, Inc.’s price range in the past 12 months?
Opus Genetics, Inc. lowest stock price was $1.04 and its highest was $5.81 in the past 12 months.
What is Opus Genetics, Inc.’s market cap?
Opus Genetics, Inc.’s market cap is $306.32M.
When is Opus Genetics, Inc.’s upcoming earnings report date?
Opus Genetics, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 4 days.
How were Opus Genetics, Inc.’s earnings last quarter?
Opus Genetics, Inc. released its earnings results on May 12, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.134 by -$0.616.
Is Opus Genetics, Inc. overvalued?
According to Wall Street analysts Opus Genetics, Inc.’s price is currently Undervalued.
Does Opus Genetics, Inc. pay dividends?
Opus Genetics, Inc. does not currently pay dividends.
What is Opus Genetics, Inc.’s EPS estimate?
Opus Genetics, Inc.’s EPS estimate is -0.16.
How many shares outstanding does Opus Genetics, Inc. have?
Opus Genetics, Inc. has 82,565,834 shares outstanding.
What happened to Opus Genetics, Inc.’s price movement after its last earnings report?
Opus Genetics, Inc. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.134. Following the earnings report the stock price went up 1.172%.
Which hedge fund is a major shareholder of Opus Genetics, Inc.?
Currently, no hedge funds are holding shares in IRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opus Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.23 (264.64% Upside)
$11.23 (264.64% Upside)
Blogger Sentiment
Neutral
IRD Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 135.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
183.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
38.66%
Trailing 12-Months
Company Description
Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
IRD Stock 12 Month Forecast
Average Price Target
$11.23
▲(264.64% Upside)
Technical Analysis
Ownership Overview
13.94% Insiders
3.51% Mutual Funds
0.33% Other Institutional Investors
75.43% Public Companies and Individual Investors